TEAD1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL850516	0.50	10/20
SCHEMBL1169872	0.51	7/20
SCHEMBL2618960	0.43	5/20
SCHEMBL2632149	0.43	5/20
SCHEMBL2216389	0.64	4/20
SCHEMBL2216396	0.64	4/20
SCHEMBL2804476	0.56	4/20
SCHEMBL2802531	0.54	4/20
SCHEMBL1818801	0.54	4/20
SCHEMBL2032041	0.54	4/20
SCHEMBL2312529	0.54	4/20
SCHEMBL2260292	0.44	4/20
SCHEMBL766090	0.41	4/20
SCHEMBL2364927	0.39	4/20
SCHEMBL2470940	0.58	3/20
SCHEMBL1980206	0.57	3/20
SCHEMBL2438027	0.56	3/20
Hydrochloric Acid (SCHEMBL2311784)	0.55	3/20
Hydrochloric Acid (SCHEMBL2311786)	0.55	3/20
SCHEMBL2089924	0.53	3/20

Clinical trials — most relevant to TEAD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
α-TEA in Advanced Cancer	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Patient's Derived Organoids for Drug Screening in Glioblastoma	nan	NOT_YET_RECRUITING
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Green Tea Anticancer Mechanisms in Smokers	nan	COMPLETED
EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells	nan	UNKNOWN
Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy	nan	NOT_YET_RECRUITING
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α.	nan	UNKNOWN
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Family Resilience Initiative Research Program	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TEAD1 binder may also engage these)

Protein	Name	Similarity
P30051	—	1.000	P30051 →
P70210	—	1.000	P70210 →
TEAD4	Transcriptional enhancer factor TEF-3	1.000	landscape →
Q62296	—	1.000	Q62296 →
Q90701	—	0.998	Q90701 →
TEAD3	Transcriptional enhancer factor TEF-5	0.995	landscape →
P48984	—	0.994	P48984 →
P30052	—	0.992	P30052 →
Q19849	—	0.989	Q19849 →
TEAD2	Transcriptional enhancer factor TEF-4	0.985	landscape →
P48301	—	0.985	P48301 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.983	landscape →
P70662	—	0.983	P70662 →
Q6GL65	—	0.982	Q6GL65 →
Q9XSK8	—	0.982	Q9XSK8 →
Q8BHR2	—	0.982	Q8BHR2 →
Q6P9Z1	—	0.981	Q6P9Z1 →
Q9JJP2	—	0.981	Q9JJP2 →
Q9JHD2	—	0.981	Q9JHD2 →
Q60520	—	0.981	Q60520 →
Q8TC92	—	0.981	Q8TC92 →
Q02225	—	0.981	Q02225 →
Q5FWH3	—	0.980	Q5FWH3 →
Q96N67	—	0.980	Q96N67 →
O43439	—	0.980	O43439 →
Q6INP8	—	0.980	Q6INP8 →
SIN3A	Paired amphipathic helix protein Sin3a	0.980	landscape →
Q17JT4	—	0.980	Q17JT4 →
Q8R1A4	—	0.980	Q8R1A4 →
SMARCC1	SWI/SNF complex subunit SMARCC1	0.980	landscape →